CURIS (CURIS) fundamentals
CURIS is a listed company, part of the Pharmaceuticals sector, listed on the NSE as CURIS (ISIN INE1BZN01016). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What CURIS does
Curis Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral Liquid, and Sterile Ophthalmic Ointments. The Company manufactures activities on loan license, Contract Manufacturing and Direct Export basis/Own Brand Marketing basis. Its products include general pharmaceutical tablets, general pharmaceutical capsules, general oral liquid, general external preparation, and sterile ophthalmic ointment. Its pharmaceutical tablets are solid dosage form of medication used for delivering active pharmaceutical ingredients. Its sterile ophthalmic ointment is a type of medication formulated for use in the eyes. Its oral liquid is versatile form of medication to be taken by mouth.
Valuation and market data
| Last close | ₹198.35 |
|---|---|
| Market capitalisation | ₹118 crore |
| Enterprise value | ₹126 crore |
| P/E (TTM) | 1.40 |
| Price to book | 7.26 |
| Price to sales (TTM) | 0.84 |
| Book value per share | ₹27.33 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹61 crore | ₹10 crore | ₹7 crore | 0.00 |
| Mar 2025 | ₹50 crore | ₹8 crore | ₹6 crore | 10.29 |
| Mar 2024 | ₹36 crore | ₹7 crore | ₹5 crore | 107.13 |
| Mar 2023 | ₹36 crore | ₹2 crore | ₹1 crore | 24.52 |
| Mar 2022 | ₹24 crore | ₹1 crore | ₹0 crore | 9.85 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 68.0% |
|---|---|
| Foreign institutions (FII) | 1.2% |
| Mutual funds | 0.0% |
| Other domestic institutions | 5.8% |
| Retail and others | 25.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.